Literature DB >> 18342947

Gram-negative organisms predominate in Hickman line-related infections in non-neutropenic patients with hematological malignancies.

L Chee1, M Brown, J Sasadeusz, L MacGregor, A P Grigg.   

Abstract

BACKGROUND: Catheter-related blood stream infections (CRBSI) cause significant morbidity and mortality in patients with hematological malignancies. Previous studies have identified a predominance of gram-positive organisms causing CRBSI but they included both neutropenic and non-neutropenic patients with solid organ and hematological malignancies. The aim of our study was to evaluate the incidence and microbiological profile of CRBSIs in a specific cohort of patients with hematological malignancies in their non-neutropenic phase of illness.
METHODS: A detailed retrospective review was done from January 2003 to December 2005 on all patients with hematological malignancies who had double-lumen non-antibiotic impregnated tunneled CVCs (Hickman catheters) inserted in our hospital to identify those fulfilling our criteria for CRBSI episodes.
RESULTS: Amongst 273 evaluable patients, 61 developed CRBSI on 70 occasions. In contrast to previous studies, there was a predominance of gram-negative infections (68%). The majority (73%) of initial CRBSI episodes required catheter removal within 7 days of onset. Vancomycin and cefepime was the most common initial antibiotic regimen used.
CONCLUSIONS: This study highlights the predominance of gram-negative infections in our cohort of non-neutropenic patients with underlying hematological malignancies who had Hickman catheters whose lines were not salvageable in the majority of cases. Empiric monotherapy with an antimicrobial agent with broad spectrum gram-negative cover needs to be given upfront pending results of the nature and sensitivity of organisms identified.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18342947     DOI: 10.1016/j.jinf.2008.01.046

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  6 in total

1.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.

Authors:  Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

2.  Catheter management across patients with hematologic malignancies and catheter-related blood stream infections: a systematic review.

Authors:  Kiyan Heybati; Rena Seeger; Santhosh Thyagu; Joshua Piticaru; Nanki Ahluwalia; Laveena Munshi
Journal:  Ann Hematol       Date:  2022-09-15       Impact factor: 4.030

3.  Concentrated citrate locking in order to reduce the long-term complications of central venous catheters: a randomized controlled trial in patients with hematological malignancies.

Authors:  R S Boersma; K S Jie; A C Voogd; K Hamulyak; A Verbon; H C Schouten
Journal:  Support Care Cancer       Date:  2014-06-20       Impact factor: 3.603

4.  Current strategies for the prevention and management of central line-associated bloodstream infections.

Authors:  Zhuolin Han; Stephen Y Liang; Jonas Marschall
Journal:  Infect Drug Resist       Date:  2010-11-23       Impact factor: 4.003

5.  Clinical characteristics of peripheral venous catheter-associated gram-negative bloodstream infection among patients with malignancy.

Authors:  Toshiharu Sasaki; Sohei Harada; Shungo Yamamoto; Daisuke Ohkushi; Brian Hayama; Koichi Takeda; Kosuke Hoashi; Joji Shiotani; Kazumi Takehana; Yohei Doi
Journal:  PLoS One       Date:  2020-01-30       Impact factor: 3.240

6.  The effects of TGF-β1 on staphylococcus epidermidis biofilm formation in a tree shrew biomaterial-centered infection model.

Authors:  Yujie Lei; Yushan Xu; Peng Jing; Bingquan Xiang; Keda Che; Junting Shen; Minjie Ning; Ying Chen; Yunchao Huang
Journal:  Ann Transl Med       Date:  2021-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.